Ipamorelin vs Sermorelin: Growth Hormone Peptides Compared

Ipamorelin and sermorelin are both discussed as growth-hormone peptides, but they are not interchangeable. Sermorelin is a GHRH analog. Ipamorelin is a ghrelin-receptor / growth hormone secretagogue receptor agonist.

That receptor difference changes how they are used, how they are stacked, and how strong the clinical evidence is.

Question	Ipamorelin	Sermorelin
Class	Growth hormone-releasing peptide / GHSR agonist.	Growth hormone-releasing hormone analog.
Main receptor	Ghrelin / growth hormone secretagogue receptor.	GHRH receptor.
Regulatory history	Research peptide; not an FDA-approved drug.	Previously FDA-approved for pediatric GH deficiency/diagnosis, later discontinued commercially.
Best evidence	Early pharmacology and human PK/PD work.	Clinical history in pediatric GH deficiency and diagnostic testing.
Practical read	More selective GHSR-style peptide, but less mainstream clinical use.	Older, better-characterized GHRH analog, but original product is discontinued.

Mechanism

Ipamorelin

Ipamorelin acts through the growth hormone secretagogue receptor, the same general receptor system involved in ghrelin signaling. Early pharmacology described it as a selective GH secretagogue with less cortisol and ACTH stimulation than older secretagogues.

That selectivity is the main reason people compare it favorably with older GHRPs like GHRP-6 or hexarelin. It does not mean ipamorelin is proven as an anti-aging drug.

Sermorelin

Sermorelin is the first 29 amino acids of growth hormone-releasing hormone (GHRH), the active region that signals the pituitary to release GH. It works upstream through the GHRH receptor rather than the ghrelin/GHSR pathway.

This gives sermorelin a more "physiologic replacement signal" story, but its effect still depends on pituitary reserve, age, baseline GH/IGF-1 status and clinical context.

Evidence

Evidence layer	Ipamorelin	Sermorelin
Human GH response data	Yes, including pharmacokinetic/pharmacodynamic modeling in volunteers.	Yes, including clinical use in pediatric GH deficiency and GH stimulation testing.
Long-term adult outcome data	Limited.	Limited for modern anti-aging/body-composition use.
Regulated product history	No FDA-approved product.	Former FDA-approved product; commercially discontinued.
Best use of the evidence	Understanding receptor selectivity and GH pulse response.	Understanding GHRH analog physiology and historical clinical use.

Side Effects and Monitoring

Both peptides aim to raise GH/IGF-1 signaling. That means the risk discussion is not just injection-site irritation. Clinicians commonly watch IGF-1 levels, glucose/insulin markers, edema, carpal-tunnel-like symptoms, headaches, blood pressure and underlying cancer risk context.

Ipamorelin's appeal is its selective GH secretagogue profile. Sermorelin's appeal is its older GHRH analog history. Neither removes the need for medical screening if GH/IGF-1 is being intentionally manipulated.

Which is Better?

There is no universal winner.

• Choose sermorelin in research contexts where a GHRH analog with a longer clinical history is the priority.
• Choose ipamorelin in research contexts where GHSR selectivity and lower cortisol/prolactin stimulation are the main comparison points.
• Avoid treating either as a shortcut to prescription HGH. These are upstream secretagogues, not direct GH replacement.

For deeper background, read the sermorelin guide and the ipamorelin database entry.

FAQ

Is ipamorelin better than sermorelin?

Not categorically. Ipamorelin is more selective at the GHSR pathway; sermorelin has a clearer GHRH analog history. The better choice depends on the clinical or research question.

Do ipamorelin and sermorelin increase IGF-1?

They can increase downstream GH/IGF-1 signaling when the pituitary and liver respond. Monitoring usually focuses on IGF-1 rather than subjective effects.

Is sermorelin FDA approved?

Sermorelin was previously FDA approved, but the original manufactured product was discontinued. Availability now is generally discussed through compounding and clinical practice, not a currently marketed brand-name product.

Is ipamorelin FDA approved?

No. Ipamorelin is not an FDA-approved drug.

References

1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue.

2. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers.

3. Prakash A, Goa KL. Sermorelin review in pediatric growth hormone deficiency.

4. Sigalos JT, Pastuszak AW. Safety and efficacy of growth hormone secretagogues review.

5. PubMed. Detection of GHRH synthetic analogs including sermorelin.